MANAGEMENT OF DIABETES-ASSOCIATED COGNITIVE IMPAIRMENT: EMERGING THERAPEUTIC APPROACHES

Diabetes mellitus represents a chronic metabolic condition defined by sustained hyperglycemia, which stems from defective insulin secretion, compromised insulin action, or a combination of both. Extending beyond its established vascular and metabolic sequelae, an accumulating body of evidence indicates that diabetes plays a substantial role in the pathogenesis of cognitive decline. Persons afflicted with diabetes face an elevated susceptibility to memory deterioration, diminished learning capacity, disrupted executive function, and neurodegenerative pathologies, including Alzheimer's disease. The etiology of these neurological consequences is multifactorial, encompassing insulin resistance, chronic hyperglycemia, oxidative stress, neuroinflammation, mitochondrial dysfunction, vascular irregularities, and compromised neuronal signaling. Existing therapeutic approaches to diabetes-associated cognitive impairment are chiefly predicated on enhancing cognitive performance and decelerating the trajectory of the disease. While conventional pharmacological interventions, specifically donepezil and memantine, have yielded only marginal improvements, emerging antidiabetic therapies, particularly GLP-1 receptor agonists, have exhibited considerable promise in terms of neuroprotection. Furthermore, a range of phytochemicals, notably curcumin, resveratrol, and berberine, have garnered significant interest due to their robust antioxidant and anti-inflammatory properties. Among these naturally derived substances, usnic acid—a dibenzofuran derivative sourced from lichens—has recently surfaced as a compelling candidate for neuroprotective therapy. Consequently, a more rigorous exploration of usnic acid within experimental frameworks modeling diabetes-induced cognitive impairment holds the potential to yield critical insights for formulating efficacious, cost-effective, and secure therapeutic strategies aimed at mitigating or managing cognitive deterioration linked to diabetes.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-17
DOI
https://doi.org/10.5281/zenodo.24306094
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

MANAGEMENT OF DIABETES-ASSOCIATED COGNITIVE IMPAIRMENT: EMERGING THERAPEUTIC APPROACHES

Nomula Pavani, Syeda Sumaiya, M. Sreekanth
2 links
Zenodo (CERN European Organization for Nuclear Research)
Alzheimer's disease research and treatments
article

MANAGEMENT OF DIABETES-ASSOCIATED COGNITIVE IMPAIRMENT: EMERGING THERAPEUTIC APPROACHES

Nomula Pavani, Syeda Sumaiya, M. Sreekanth
article en

Abstract

Diabetes mellitus represents a chronic metabolic condition defined by sustained hyperglycemia, which stems from defective insulin secretion, compromised insulin action, or a combination of both. Extending beyond its established vascular and metabolic sequelae, an accumulating body of evidence indicates that diabetes plays a substantial role in the pathogenesis of cognitive decline. Persons afflicted with diabetes face an elevated susceptibility to memory deterioration, diminished learning capacity, disrupted executive function, and neurodegenerative pathologies, including Alzheimer's disease. The etiology of these neurological consequences is multifactorial, encompassing insulin resistance, chronic hyperglycemia, oxidative stress, neuroinflammation, mitochondrial dysfunction, vascular irregularities, and compromised neuronal signaling. Existing therapeutic approaches to diabetes-associated cognitive impairment are chiefly predicated on enhancing cognitive performance and decelerating the trajectory of the disease. While conventional pharmacological interventions, specifically donepezil and memantine, have yielded only marginal improvements, emerging antidiabetic therapies, particularly GLP-1 receptor agonists, have exhibited considerable promise in terms of neuroprotection. Furthermore, a range of phytochemicals, notably curcumin, resveratrol, and berberine, have garnered significant interest due to their robust antioxidant and anti-inflammatory properties. Among these naturally derived substances, usnic acid—a dibenzofuran derivative sourced from lichens—has recently surfaced as a compelling candidate for neuroprotective therapy. Consequently, a more rigorous exploration of usnic acid within experimental frameworks modeling diabetes-induced cognitive impairment holds the potential to yield critical insights for formulating efficacious, cost-effective, and secure therapeutic strategies aimed at mitigating or managing cognitive deterioration linked to diabetes.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon